CORDIS · 115523 · FP7
COMBACTE-NET Combatting Bacterial Resistance in Europe
Coordinator: ASTRAZENECA AB (SE)
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial …
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €109.4M toward a total project budget of €221.0M — a funding rate of 50%, with the remainder covered by the consortium partners. The project runs over approximately 8.2 years from 2013-01-01 to 2021-02-28.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from SE
see all →- GrapheneCore1 — Graphene-based disruptive technologies696656 · H2020 · €89.0M
- GrapheneCore2 — Graphene Flagship Core Project 2785219 · H2020 · €88.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · FP7 · €75.3M
- 2D-EPL — Graphene Flagship 2D Experimental Pilot Line952792 · H2020 · €20.0M
- BrightnESS — Building a research infrastructure and synergies for highest scientific impact on ESS676548 · H2020 · €19.9M
- LOCOMACHS — LOw COst Manufacturing and Assembly of Composite and Hybrid Structures314003 · FP7 · €19.6M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
- GSC DA — GMES Space Component Data Access223001 · FR · €48.0M
- MAAXIMUS — More Affordable Aircraft structure through eXtended, Integrated, and Mature nUmerical Sizing213371 · DE · €40.2M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
- What is the EU contribution?
- The European Commission contributes €109.4M toward a total project budget of €221.0M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by ASTRAZENECA AB (SE).
- What is the project timeline?
- The project runs from 2013-01-01 to 2021-02-28 — approximately 8.2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115523.